Bayer closed 2023 with a 3% increase in sales in Spain, although the German company refers to its commitment to innovation as the real driver of its growth. This was made clear in the presentation of its results, in which it highlights the investment of 154.3 million euros it made in Spain last year.

2024 will mark 125 years of Bayer being present in Spain. The multinational has begun to celebrate the anniversary by publishing, for the first time, the consolidated data of the investment made in the advanced therapy centres it has in San Sebastian: Viralgen and TAAV. It spent a total of 86.8 million euros on these two facilities.

Increased production capacity
The presentation of the results took place at the Berlimed plant in Alcalá de Henares (Madrid). The launch of these facilities in 2023 closed the investment plan started in 2019, which has amounted to 74 million euros. The factory, which produces and develops medicines, has expanded its production capacity with this plan, both in contrast media for radiology and therapeutic treatments in liquid form, and in addition to soft gelatine capsules for anti-flu, multivitamin, gastrointestinal, analgesic and dermatological products and food supplements.

Berlimed is also the only Bayer centre specialising in food supplements worldwide. Most of the investments went to expanding production capacity, advances in technification and digitalisation to make resources more efficient, increased connectivity and improved process monitoring. New support buildings have also been constructed to facilitate access to its facilities, changing rooms and storage and distribution of its drugs.

Scientific talent
Bayer's CEO for Spain and Portugal, Bernardo Kanahuati, said, “We are proud to be able to celebrate 125 years in Spain with solid growth and a strengthening of our investments. This is also a moment to celebrate and thank all the professionals whose daily work has made our growth possible in the country over the years and, above all, the enormous scientific talent that, through collaboration, has enabled our innovation to develop and has contributed to our ‘health and food for all’ mission.”

Since 2019, Bayer has reduced its carbon dioxide emissions in Spain by 38% across its entire value chain. Its sales in Spain grew by over 3% in 2023 to reach 768 million euros. The figures reflect growth in all its three areas of activity: 397 million euros in prescription medicines (up 1.8% on the previous year), 256 million euros in agriculture (up 2.8%) and 115 million euros in self-care (up 7.5%).

^{Photo: Bayer}